You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

Article metrics

Article menu

Download PDFPDF

Treatments
Short report
Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study

 

Online download statistics by month:

Online download statistics by month: March 2022 to March 2024

AbstractFullPdf
Mar 2022360352154
Apr 202211811863
May 2022858636
Jun 2022999725
Jul 2022807722
Aug 2022626114
Sep 2022636432
Oct 2022787825
Nov 2022666436
Dec 2022585430
Jan 2023403829
Feb 2023524520
Mar 2023595535
Apr 2023262421
May 2023362916
Jun 2023363511
Jul 2023303015
Aug 202313137
Sep 202312117
Oct 2023333220
Nov 202322223
Dec 2023242213
Jan 2024191912
Feb 2024232015
Mar 2024202070
Total15141466731